Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (351-360 of 692) with videos related to

Pageof 70
Sort By:
Urology|May 29, 2002
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancerMichael J Morris, Timothy Akhurst, Iman Osman, et al.
Journal of Clinical Epidemiology|January 1, 1988
Day hospital as an alternative to inpatient care for cancer patients: a random assignment trialV Mor, M Z Stalker, R Gralla, et al.
Cancer|August 1, 1984
Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamideT Ahmed, P Benedetto, A Yagoda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1990
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory diseaseH I Scher, T Curley, N Geller, et al.
Cephalalgia : an International Journal of Headache|March 11, 2020
The prevalence of hypnic headache in IcelandJon H Eliasson, Ann I Scher, Dawn C Buse, et al.
European Urology Focus|February 27, 2026
ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapyAndrew L Laccetti, Matthew R Smith, Howard I Scher, et al.
Biochimica Et Biophysica Acta|February 27, 1986
Influence of vesicle size on complement-dependent immune damage to liposomesR L Richards, R C Habbersett, I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, H Herr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trialC N Sternberg, J S de Bono, K N Chi, et al.
The Prostate|December 16, 1997
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissueT Bogenrieder, C L Finstad, R H Freeman, et al.
Pageof 70

Showing results (351-360 of 692) with videos related to

Sort By:
Pageof 70
Urology|May 29, 2002
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancerMichael J Morris, Timothy Akhurst, Iman Osman, et al.
Journal of Clinical Epidemiology|January 1, 1988
Day hospital as an alternative to inpatient care for cancer patients: a random assignment trialV Mor, M Z Stalker, R Gralla, et al.
Cancer|August 1, 1984
Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamideT Ahmed, P Benedetto, A Yagoda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1990
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory diseaseH I Scher, T Curley, N Geller, et al.
Cephalalgia : an International Journal of Headache|March 11, 2020
The prevalence of hypnic headache in IcelandJon H Eliasson, Ann I Scher, Dawn C Buse, et al.
European Urology Focus|February 27, 2026
ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapyAndrew L Laccetti, Matthew R Smith, Howard I Scher, et al.
Biochimica Et Biophysica Acta|February 27, 1986
Influence of vesicle size on complement-dependent immune damage to liposomesR L Richards, R C Habbersett, I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinomaP M Dodd, J A McCaffrey, H Herr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trialC N Sternberg, J S de Bono, K N Chi, et al.
The Prostate|December 16, 1997
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissueT Bogenrieder, C L Finstad, R H Freeman, et al.
Pageof 70